Home › Leukemia › Utah › Salt Lake City
Leukemia clinical trials in Salt Lake City, UT
4 studies for Leukemia are looking for participants at sites in and around Salt Lake City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RecruitingPhase 2
- Huntsman Cancer Institute, Salt Lake City
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingPhase 2
- Primary Children's Hospital, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Salt Lake City
About Leukemia
Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.
More about Leukemia on MedlinePlus
Leukemia trials in other cities
- Houston, TX28 studies
- Boston, MA25 studies
- New York City, NY19 studies
- Los Angeles, CA16 studies
- Chicago, IL16 studies
- Durham, NC13 studies
- Baldwin Park, CA12 studies
- Nashville, TN12 studies
- Columbus, OH12 studies
- Philadelphia, PA12 studies
- Milwaukee, WI11 studies
- Atlanta, GA11 studies
Other studies in Salt Lake City
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)27 studies
- Breast Cancer27 studies
- Colorectal Cancer21 studies
- Lung Cancer21 studies
- Multiple Myeloma21 studies
- Melanoma21 studies
- Metastatic Cancer20 studies
- Ovarian Cancer19 studies
- Obesity18 studies
- Acute Myeloid Leukemia17 studies
- Heart Failure17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.